Fundraising FoxTrames Bio
1 known investors
Find your way into Trames Bio
Sign up to see every warm intro you have to Trames Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Trames Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Trames Bio is a biotech company developing gene therapies for chronic neuropathic pain, using chemogenetics to deliver an AAV-encoded inhibitory ion channel to specific pain neurons that is then activated by an oral small molecule for on-demand, reversible nerve block. Its initial focus is on trigeminal neuralgia and lumbosacral radiculopathy, with broader applications to other pain and CNS disorders.
Investors · 1
Frequently asked questions
- What does Trames Bio do?
- Trames Bio is a biotech company developing gene therapies for chronic neuropathic pain, using chemogenetics to deliver an AAV-encoded inhibitory ion channel to specific pain neurons that is then activated by an oral small molecule for on-demand, reversible nerve block. Its initial focus is on trigeminal neuralgia and lumbosacral radiculopathy, with broader applications to other pain and CNS disorders.
- Who are Trames Bio's investors?
- Trames Bio's investors include Aditum Bio.